TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01550627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extra fluid/iv fluid supplementation during phototherapy
Description: The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non extra fluid
Description: Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
Study: NCT03220347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90010
Description: CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
Study: NCT04575064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
Study: NCT00611273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFX
Description: The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
Study: NCT04063436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New nasal pillows mask with PAP therapy
Description: Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
Study: NCT04267107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Managing Fatigue Program
Description: The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
Study: NCT03656666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets
Study: NCT01782924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Study: NCT00114166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Study: NCT03469336

Intervention type: DRUG
Group type: OTHER
Intervention: PF-06763809
Description: Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%

Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Vehicle matching PF-06763809.

Intervention type: DRUG
Group type: OTHER
Intervention: Calcipotriene/calcipotriol
Description: Calcipotriene/calcipotriol 50 ug/mL solution

Intervention type: DRUG
Group type: OTHER
Intervention: Betamethasone
Description: Betamethasone 1 mg/g solution
Study: NCT02378961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet(s) administered orally once daily with food
Study: NCT03528824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fenugreek wrap
Description: Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Gel
Description: Daily application of diclofenac gel, 4 weeks application
Study: NCT02645071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
Study: NCT02441192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training resistance
Description: After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training aerobic
Description: After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training resistance+aerobic
Description: After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
Study: NCT00763243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training Program
Description: The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
Study: NCT02687607

Intervention type: DEVICE
Intervention: WEB Aneurysm Embolization System
Study: NCT02591043

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Outcome after surgery
Description: Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
Study: NCT03743207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperature
Description: These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmer temperature
Description: Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
Study: NCT00650052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide Capsules 100 mg
Description: 100mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran® Capsules 100 mg
Description: 100mg, single dose fasting
Study: NCT03235453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binary rhythm
Description: The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quaternary rhythm
Description: The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
Study: NCT02536716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platform-matched dental implant
Description: A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platform-switched dental implant
Description: A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
Study: NCT01594840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Changing chat
Description: Diapers with tips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Changing chat
Description: Diapers with tips
Study: NCT01772550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20GA BD Nexiva Diffusics
Description: The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20GA BD Nexiva Diffusics
Description: The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18GA Conventional Catheter
Description: The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.
Study: NCT00486356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT01309204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Inactive ingredients used as a placebo for masking purposes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate 0.2% ophthalmic solution
Study: NCT03355950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein Repair
Description: Well defined Lichtenstein Repair for inguinal hernias

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP Repair
Description: Laparoscopic totally extraperitoneal repair for inguianal hernias
Study: NCT01461746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
Study: NCT01251718

Intervention type: DRUG
Intervention: donepezil hydrochloride
Description: Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Study: NCT01544101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan Diet
Description: Vegan diet, which is devoid of animal products and minimal in fat

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary supplement omega3 fatty acids aand vitamins
Description: mixture of omega3 fatty acids aand vitamins
Study: NCT01799486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg monotherapy supplied in film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enecavir
Description: 0.5 mg monotherapy supplied in tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: 10 mg monotherapy supplied in tablets.
Study: NCT04514627

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular percutaneous neurostimulation
Description: The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auricular percutaneous neurostimulation
Description: The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
Study: NCT01104402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home lung function and symptom monitoring
Description: subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
Study: NCT02776605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 30 mg, PO from day 1 to consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: VP-16: 100 mg/m2/12 h, IV, days 14 and 42

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C:
Description: ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIT
Description: TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Description: Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allo transplantation
Description: Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
Study: NCT01037335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine
Description: Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
Study: NCT04267887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given ADT per standard of care
Study: NCT00105560

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy with proton beam to standard doses
Study: NCT02295800

Intervention type: OTHER
Intervention: Standard of care

Intervention type: OTHER
Intervention: Standard of care

Intervention type: OTHER
Intervention: Semi-structured interviews

Intervention type: OTHER
Intervention: Semi-structured interviews
Study: NCT06082375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3 in the form of cholecalciferol.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vegetable oil.
Study: NCT03919006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid, saliva and serum collection
Description: GCF with filter paper using the intracrevicular method, saliva and serum collection
Study: NCT01001234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan
Description: For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan
Description: For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder \[moderate or severe pain 15 minutes after dose\] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
Study: NCT01200160

Intervention type: DRUG
Intervention: Niacin
Study: NCT03271060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lumbar interbody fusion
Description: Lumbar fusion by screws and inter vertebral cage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inter transverse bone grafting
Description: Inter transverse process bone grafting by bone graft from illiac crest or other sites